A series of stapled BCL-2 family peptide helices wereidentified as able to target the survival protein MCL-I with high affinityand a subset with unprecedented selectivity. Agents and methods forselective pharmacologic neutralization of MCL-I are provided for drugdiscovery and therapeutic uses, including use in overcoming the apoptoticresistance of cancer and other diseases associated with impairedcell death.
